Corvus Pharmaceuticals (CRVS) Share-based Compensation (2015 - 2026)

Corvus Pharmaceuticals' Share-based Compensation history runs 12 years deep, the most recent figure standing at $2.6 million for Q1 2026.

• In Q1 2026, Share-based Compensation rose 111.83% year-over-year to $2.6 million; the TTM figure through Mar 2026 stood at $6.7 million (up 88.8% YoY), while the FY2025 annual figure was $5.3 million, up 77.49% from the prior year.
• Share-based Compensation was $2.6 million for Q1 2026 at Corvus Pharmaceuticals, up from $1.6 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $2.6 million in Q1 2026 to a low of $492000.0 in Q1 2023.
• Historically, Share-based Compensation has averaged $930647.1 across 5 years, with a median of $733000.0 in 2024.
• The sharpest annual moves came in 2022 and 2026: Share-based Compensation plunged 42.46% in 2022, then jumped 111.83% in 2026.
• A 5-year view of Share-based Compensation shows it stood at $620000.0 in 2022, then declined by 7.74% to $572000.0 in 2023, then jumped by 41.96% to $812000.0 in 2024, then soared by 93.84% to $1.6 million in 2025, then surged by 68.36% to $2.6 million in 2026.
• The last three Share-based Compensation figures came in at $2.6 million (Q1 2026), $1.6 million (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.